Trial · NCT00424749
Rituxan in Churg Strauss Syndrome With Renal Involvement
NCT00424749, Phase 2, Terminated, Fernando Fervenza; results first posted 2011-12-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituxan in Churg Strauss Syndrome With Renal Involvement. Trials, record NCT00424749. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00424749
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituxan in Churg Strauss Syndrome With Renal Involvement
- NCT number
- NCT00424749
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- Fernando Fervenza
- Conditions
- Churg-Strauss Syndrome
- Interventions
- Rituximab, Prednisone
- First posted
- 2007-01-22
- Last updated
- 2011-12-08
- Results first posted
- 2011-12-08
- Limitations and caveats
The limited number of individuals enrolled into the study makes it difficult to draw firm conclusions that are more than hypothesis generating. The company providing study drug terminated study due to lack of funds.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Participants With Remission of Renal Disease Activity at 3 Months | 3 months after beginning of remission induction regimen | Remission of renal disease activity was indicated by stable or falling creatinine, absence of active urinary sediment AND reduction of oral prednisone dose to less than 50% of average dose of preceding 3 months or less than 10 mg/day (whichever smaller) |
| Secondary | Participants With Normalization of Eosinophil Count at 6 Months | 6 months after beginning of remission induction regimen | Normalization of eosinophil counts was defined as total eosinophil counts \<1.5 x 10\^9/L. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Participants With Normalization of Eosinophil Count at 6 Months | 6 months after beginning of remission induction regimen | participants | NUMBER | |
| PRIMARY | Participants With Remission of Renal Disease Activity at 3 Months | 3 months after beginning of remission induction regimen | participants | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants With Normalization of Eosinophil Count at 6 Months | Rituximab | 2 | participants | ||
| Participants With Remission of Renal Disease Activity at 3 Months | Rituximab | 3 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Rituximab | 4 | |
| Overall Study | COMPLETED | Rituximab | 3 | |
| Overall Study | NOT COMPLETED | Rituximab | 1 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper Respiratory Tract Infection | Respiratory, thoracic and mediastinal disorders | Rituximab | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Rituximab | ||
| Total, other adverse events | Rituximab | 1 | 3 |
| Total, serious adverse events | Rituximab | 0 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 21325353 | RESULT |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1RR024150 | Mayo Clinic Center for Translational Science Activities | RIZZA, ROBERT A. | MAYO CLINIC ROCHESTER | NATIONAL CENTER FOR RESEARCH RESOURCES | 2006 to 2011 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00424749
GET https://conductscience.org/api/trials/v1/NCT00424749/registered